{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:33:10Z","timestamp":1776454390820,"version":"3.51.2"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lipidjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jacl.2018.02.005","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T13:00:55Z","timestamp":1518613255000},"page":"643-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Predictors of a successful statin reattempt after an adverse reaction"],"prefix":"10.1016","volume":"12","author":[{"given":"Huabing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Plutzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Shubina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-564X","authenticated-orcid":false,"given":"Alexander","family":"Turchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2018.02.005_bib1","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.02.005_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.02.005_bib3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2018.02.005_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2018.02.005_bib5","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.02.005_bib6","doi-asserted-by":"crossref","first-page":"6314","DOI":"10.2174\/1381612820666140620162629","article-title":"Statin treatment non-adherence and discontinuation: clinical implications and potential solutions","volume":"20","author":"Phan","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacl.2018.02.005_bib7","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2018.02.005_bib8","doi-asserted-by":"crossref","first-page":"i3305","DOI":"10.1136\/bmj.i3305","article-title":"Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database","volume":"353","author":"Vinogradova","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2018.02.005_bib9","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.2174\/138161211798220891","article-title":"Statin discontinuation in high-risk patients: a systematic review of the evidence","volume":"17","author":"Gomez Sandoval","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacl.2018.02.005_bib10","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.02.005_bib11","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.02.005_bib12","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.02.005_bib13","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2018.02.005_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000368914","article-title":"Reasons for discontinuation of lipid-lowering medications in patients with chronic kidney disease","volume":"4","author":"Morrison","year":"2014","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.jacl.2018.02.005_bib15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","article-title":"Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education","volume":"7","author":"Wei","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.02.005_bib16","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.02.005_bib17","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2018.02.005_bib18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2018.02.005_bib19","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.2016.16557","article-title":"What to believe and do about statin-associated adverse effects","volume":"316","author":"Thompson","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2018.02.005_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/M16-0838","article-title":"Continued statin prescriptions after adverse reactions and patient outcomes: a cohort study","volume":"167","author":"Zhang","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2018.02.005_bib21","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jacl.2016.06.008","article-title":"Management strategies in patients with statin-associated muscle symptoms: What is the best strategy?","volume":"10","author":"Joy","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.02.005_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2018.02.005_bib23","unstructured":"FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. Vol 20162011. Available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm256581.htm."},{"key":"10.1016\/j.jacl.2018.02.005_bib24","unstructured":"Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Vol\u00a020162014. Available at: https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/DrugInteractionsLabeling\/ucm093664.htm."},{"key":"10.1016\/j.jacl.2018.02.005_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2018.02.005_bib26","doi-asserted-by":"crossref","first-page":"447","DOI":"10.4338\/ACI-2017-01-IE-0018","article-title":"Canary: an NLP Platform for Clinicians and Researchers","volume":"8","author":"Malmasi","year":"2017","journal-title":"Appl Clin Inform"},{"key":"10.1016\/j.jacl.2018.02.005_bib27","first-page":"1270","article-title":"Structured vs. unstructured: factors affecting adverse drug reaction documentation in an EMR repository","volume":"2011","author":"Skentzos","year":"2011","journal-title":"Proc AMIA Symp"},{"key":"10.1016\/j.jacl.2018.02.005_bib28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/biomet\/73.3.751","article-title":"An improved Bonferroni procedure for multiple tests of significance","volume":"73","author":"Simes","year":"1986","journal-title":"Biometrika"},{"key":"10.1016\/j.jacl.2018.02.005_bib29","first-page":"800","volume":"Vol 75","author":"Hochberg","year":"1988"},{"key":"10.1016\/j.jacl.2018.02.005_bib30","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2018.02.005_bib31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/jamainternmed.2015.7248","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors for treatment of high cholesterol levels: effectiveness and value","volume":"176","author":"Tice","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacl.2018.02.005_bib32","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2018.02.005_bib33","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/j.1755-5922.2011.00267.x","article-title":"Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge","volume":"30","author":"Fung","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jacl.2018.02.005_bib34","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/j.jacl.2014.03.002","article-title":"The National Lipid Association Statin Intolerance P. An assessment by the Statin Intolerance Panel: 2014 update","volume":"8","author":"Guyton","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2018.02.005_bib35","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1525-1497.2004.30516.x","article-title":"Suboptimal statin adherence and discontinuation in primary and secondary prevention populations","volume":"19","author":"Ellis","year":"2004","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jacl.2018.02.005_bib36","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2018.02.005_bib37","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1365-2125.2005.02355.x","article-title":"Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention","volume":"59","author":"Perreault","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2018.02.005_bib38","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.amjmed.2011.12.013","article-title":"Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients","volume":"125","author":"Naderi","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2018.02.005_bib39","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016)","volume":"32","author":"Mancini","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2018.02.005_bib40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2018.02.005_bib41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","article-title":"The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability","volume":"31","author":"Rosenson","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2018.02.005_bib42","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1467-9450.1963.tb01330.x","article-title":"Psychophysiological reactions to two different placebo treatments","volume":"4","author":"Frankenhaeuser","year":"1963","journal-title":"Scand J Psychol"},{"key":"10.1016\/j.jacl.2018.02.005_bib43","doi-asserted-by":"crossref","first-page":"e0140967","DOI":"10.1371\/journal.pone.0140967","article-title":"Different placebos, different mechanisms, different outcomes: lessons for clinical trials","volume":"10","author":"Benedetti","year":"2015","journal-title":"PLoS One"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418300564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418300564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,16]],"date-time":"2018-06-16T11:09:17Z","timestamp":1529147357000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287418300564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1933287418300564"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2018.02.005","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of a successful statin reattempt after an adverse reaction","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2018.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}